A brief history of hepatitis milestones

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 29-37

  Trepo, Christian ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Antivirals; HAV; HCV; HDV; Hepatitis B; Hepatitis C; History; Interferon; Liver; Nucleoside analogs; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HEPATITIS VACCINE; NUCLEOSIDE ANALOG;

ANTIVIRAL THERAPY; DELTA AGENT HEPATITIS; HEPADNAVIRUS; HEPATITIS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E; HEPATITIS NON A NON B; HUMAN; JAUNDICE; REVIEW; VIRUS IDENTIFICATION;

ANTIVIRALS; HAV; HCV; HDV; HEPATITIS B; HEPATITIS C; HISTORY; INTERFERON; LIVER; NUCLEOSIDE ANALOGS; VACCINE;

DISEASE ERADICATION; DRUG THERAPY, COMBINATION; HEPATITIS; HEPATITIS VIRUSES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 84890877613     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12409     Document Type: Review

References (52)

1. Payen JL. De la jaunisse à l'hépatite C, 5000 ans d'histoire. Editions EDK: Paris, 2002.
2. Payen JL, Rongières M. Histoire des hépatites. I. De la jaunisse au virus. Rev Prat 2002; 52: 2097-100.
3. Oon GCJ. Viral hepatitis - The silent killer. Annals Academy of Medicine 2012; 41: 279-80.
4. Tygstrup N. Viral Hepatitis. Clinics in Gastroenterology 1980; 3: 281.
5. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serological follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Eng J Med 1987; 316: 965-70.
6. MacCallum F. Homologous serum hepatitis. Lancet 1947; 2: 691-2.
7. Krugman S, Gilles J, Hammond J. Infectious hepatitis - Evidence for two distinctive clinical, epidemiological, and immunological type of infection. JAMA 1967; 200: 365-73.
8. Krugman S, Gilles JP, Hammond J. Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1984; 252: 393-401.
9. Alter HJ. The road not taken or how I learned to love the liver: a personal perspective on hepatitis history. Hepatol 2013; doi: 10.1002/hep.26787.
10. Blumberg BS, Alter HJ, Visnich A. A 'new' antigen in leukemia sera. JAMA 1965; 191: 541-6.
11. Prince A. An antigen detected in blood during the inculation period of serum hepatitis. Proc Nat Arc USA 1968; 60: 814-21.
12. Dane D, Cameron CN, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-8.
13. Blumberg BS. Hepatitis B: The hunt for a killer virus. New Jersey: Princeton University Press, 2003.
14. Magnius L, Espmark J. New specificities in Australia antigen positive sera distinct from the 'Le Bouvier' determinants. J Immunology 1972; 109: 1017-21.
15. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268-73.
16. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
17. Li JS, Tong SP, Wen YM, et al. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402-10.
18. Chemin I, Guillaud O, Chevallier P, Trépo C. Close monitoring of serum, DNA levels and liver enzymes levels is most useful in patients with occult HBV infection. J Hepatol 2009; 51: 824-5.
19. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34 Suppl 1: S15-21. Review.
20. Dupinay T, Gheit T, Roques P, et al. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 2013; 58: 1610-20.
21. Bukh J, Lanford RE, Purcell RH. Persistent human hepatitis B virus infection in cynomolgus monkeys: a novel animal model in the search for a cure?. Hepatology 2013; doi: 10.1002/hep.26560.
22. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of a new antigen/antibody system (Delta/anti-Delta) associated with hepatitis B virus in liver and serum of HBsAg carriers. Gut 1977; 18: 997-1003.
23. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993; 104: 955-63.
24. Andrade ZA, Lesbordes JL, Ravisse P, et al. Fulminant hepatitis with microvesicular steatosis (a histologic comparison of cases occurring in Brazil - Labrea hepatitis - and in Central Africa - Bangui hepatitis. Revista da Sociedad Brasileira de Medicina Tropical 1992; 25: 155-60.
25. Deinhardt F, Holmes AW, Capps RB, Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. Transmission of diseases, serial passages, and description of liver lesions. J Exp Med 1967; 125: 673-88.
26. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of virus like antigen associated with acute illness. Science 1973; 200: 365-73.
27. Prince A, Brotman B, Grady G, et al. Long incubation post transfusion hepatitis without serological evidence of exposure to hepatitis B virus. Lancet 1974; 2: 2416.
28. Feinstone S, Kapikian A, Purcell R, Alter H, Holland P. Transfusion associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767-70.
29. Bradley D, MacCaustland K, Cook E, et al. Post transfusion non A-non B hepatitis in chimpanzees; physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 1985; 88: 773-9.
30. Choo Q, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-brone non A-non B viral hepatitis genome. Sicence 1989; 244: 359-62.
31. Wiewanath R. Epidemiology: infectious hepatitis in Dehli 1955-56. Indian J Med Res 1957; 45(Suppl. 1): 1-29.
32. Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pavri KM. Epidemic and endemic hepatitis in India: evidence for non A- non B hepatitis virus etiology. Lancet 1980; 2: 876-9.
33. Khuroo M, Deurmeyer W, Zargar S, Ahanger MA, Shah MA. Acute sporadic non A-non B hepatitis in India. Am J Epidemiol 1983; 118: 360-4.
34. Balayan M, Andajaparidze A, Savinskaya S, et al. Evidence for a virus in non A-non B hepatitis transmitted via the fecal-oral route. Intervirology 1983; 20: 23-31.
35. Krawczynski K, Bradely D. Enterically transmitted non A-non B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. J Infect Dis 1989; 159: 1042-9.
36. Krugmann S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971; 218: 1665-70.
37. Soulier JP, Blatix C, Couroucé AM, et al. Prevention of virus B hepatitis (SH hepatitis). Am J Dis Child 1972; 123: 429.
38. Szmuness W, Stevens C, Harley E, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United-States. N Engl J Med 1980; 303: 833-41.
39. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22, 707 men in Taiwan. Lancet 1981; 2: 1129-33.
40. Chalmers TC, Eckhardt RD, Reynolds WE, et al. The treatment of acute infectious hepatitis Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J Clin Invest 1955; 2: 1163-235.
41. Blum AL, Stutz R, Haemmerli UP, Schmid P, Grady GF. A fortuitously controlled study of steroid therapy in acute viral hepatitis. Am J Med 1969; 47: 82-92.
42. Lam KC, Lai CL, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380-6.
43. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 1995; 22: 42-4.
44. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
45. Prince AM, Trepo C. Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet 1971; 1: 1309-12.
46. Trepo C, Amiri M, Guillevin L. Extrahepatic manifestations of hepatitis B infection. In: Thomas HC, Loc AS, Locarnini SA, Zuckerman A, eds. Viral Hepatitis, 4th edn. Wiley Blakwell, 2013; 154-162.
47. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non A-non B with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
48. Bisceglie AM, Martin P, Kassianides C. et al. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. J Hepatol 1990; 11 (Suppl 1): S36-42.
49. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
50. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatits C. Hepatology 2001; 34: 395-403.
51. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 358-65.
52. Schinazi RF, Bassit C, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepatitis 2010; 17: 77-90.